当前位置: X-MOL 学术Cancer Biol. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient.
Cancer Biology & Therapy ( IF 4.4 ) Pub Date : 2019-08-18 , DOI: 10.1080/15384047.2019.1647055
Samuel Regan 1 , Xuebin Yang 2 , Niklas K Finnberg 3 , Wafik S El-Deiry 4 , Jeffrey J Pu 1, 5, 6
Affiliation  

Hydroxyurea (HU) has been widely used in sickle cell disease. Its potential long-term risk for carcinogenesis or leukemogenic risk remains undefined. Here, we report a 26 y old African-American female with Sickle Cell Disease (SCD) who developed refractory/relapsed acute myeloid leukemia (AML) 6 months after 26 months of HU use. That patient's cytogenetics and molecular genetics analyses demonstrated a complex mutation profile with 5q deletion, trisomy 8, and P53 deletion (deletion of 17p13.1). P53 gene sequence studies revealed a multitude of somatic mutations that most suggest a treatment-related etiology. The above-mentioned data indicates that the patient may have developed acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) as a direct result of HU exposure.

中文翻译:

在羟基脲治疗的镰状细胞病患者中发生急性髓细胞性白血病。

羟基脲(HU)已被广泛用于镰状细胞病。其潜在的长期致癌危险或致白血病危险仍不确定。在这里,我们报告了26岁的患有镰状细胞病(SCD)的非洲裔美国女性,在使用HU的6个月后6个月出现了难治性/复发性急性髓细胞性白血病(AML)。该患者的细胞遗传学和分子遗传学分析显示了一个复杂的突变谱,其中有5q缺失,8三体性和P53缺失(缺失17p13.1)。P53基因序列研究揭示了许多体细胞突变,大多数表明与治疗相关的病因。上述数据表明,由于HU暴露的直接结果,患者可能已发生急性骨髓性白血病,并伴有骨髓增生异常相关变化(AML-MRC)。
更新日期:2019-11-01
down
wechat
bug